David Oxlade joins TranScrip Partners
This article was originally published in Scrip
Executive Summary
TranScrip Partners, a pharmaceutical development company formed in 2008 to provide advice and support to pharmaceutical and biotechnology companies, has appointed David Oxlade chairman of the board. In 2006, Mr Oxlade was appointed chairman of BioAnaLab, which was acquired by Millipore this year. He is the former CEO of Xenova, and, prior to their acquisition by Roche, he also spent 14 years working for Boehringer Mannheim and seven years serving as president of Syva.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.